IDH2 and glioblastoma: A cohort of 137 human brain tissue samples from 109 patients was used for the development and validation of the method, including gliomas with IDH mutation and wildtype, normal brain tissues and different subtypes of gliomas such as astrocytoma, oligodendroglioma and glioblastoma.